Solaris Energy (SEI) Infrastructure announced the pricing of its public offering of $650,000,000 aggregate principal amount of 0.25% convertible senior notes due 2031. The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on October 8, 2025, subject to customary closing conditions. Solaris also granted the underwriters of the notes an option to purchase, for settlement withi ...

Core Viewpoint - Cytokinetics has announced the pricing of a $650 million offering of 1.75% convertible senior notes due 2031, increasing from a previously announced size of $550 million [1][4]. Transaction Details - The notes are set to settle on September 19, 2025, and the initial purchasers have an option to buy an additional $100 million in notes within 13 days of issuance [3]. - The notes will be senior, unsecured obligations with an annual interest rate of 1.75%, payable semi-annually starting April 1, 2026, and maturing on October 1, 2031 [4]. - Noteholders can convert their notes under specific conditions before July 1, 2031, and at any time thereafter until maturity [4]. - The initial conversion rate is 14.6156 shares per $1,000 principal amount, equating to a conversion price of approximately $68.42 per share, representing a 37.5% premium over the last reported sale price of $49.76 on September 16, 2025 [4]. Redemption and Repurchase Conditions - Cytokinetics cannot redeem the notes before October 6, 2028, but can redeem them thereafter under certain conditions [5]. - In the event of a "fundamental change," noteholders may require Cytokinetics to repurchase their notes at the principal amount plus accrued interest [6]. Use of Proceeds - The net proceeds from the offering are estimated at approximately $632 million, or $729.4 million if the option for additional notes is fully exercised [7]. - The primary use of proceeds will be to refinance existing 3.50% convertible senior notes due 2027, extending their maturity to 2031 and retiring approximately $399.5 million of those notes [7][8]. - Remaining proceeds will support the potential commercial launch of aficamten and general corporate purposes [7][14]. Company Overview - Cytokinetics is a biopharmaceutical company focused on developing new medicines for cardiac muscle dysfunction, with a pipeline that includes aficamten and omecamtiv mecarbil [12]. - Aficamten is being prepared for potential regulatory approvals following positive Phase 3 trial results, while other products target various heart failure conditions [12].

Core Viewpoint - GDS Holdings Limited has announced the pricing of a $500 million offering of 2.25% convertible senior notes due in 2032, increasing the initial offering size from $450 million, with expected net proceeds of approximately $486.1 million after expenses [1][2]. Group 1: Notes Offering Details - The offering consists of 2.25% convertible senior notes with an aggregate principal amount of $500 million, due in 2032, and is being offered to qualified institutional buyers [1]. - The company has granted initial purchasers an option to buy an additional $50 million in notes, with the offering expected to close around May 30, 2025 [1]. - The net proceeds will be used for working capital and refinancing existing debt, including potential repurchases of convertible bonds due in 2029 [2]. Group 2: Notes Characteristics - The notes will bear interest at 2.25% per year, payable semiannually, and will mature on June 1, 2032 [3]. - The initial conversion rate is set at 30.2343 American depositary shares (ADSs) per $1,000 principal amount, equating to a conversion price of approximately $33.08 per ADS, representing a 35% premium over the ADS public offering price of $24.50 [4]. - The notes are convertible under specific conditions, with holders able to convert them into cash, ADSs, or a combination thereof starting December 1, 2031 [5]. Group 3: Redemption and Repurchase Options - The company may redeem the notes under certain conditions, including tax law changes or if less than 10% of the original principal remains outstanding [6]. - Holders can require the company to repurchase their notes on June 1, 2029, or upon a "fundamental change" [7][8]. Group 4: Market Impact and Additional Offerings - The company anticipates that some purchasers may establish short positions in its ADSs, which could affect the market price of both the ADSs and the notes [9]. - GDS Holdings has also priced a separate public offering of 6,000,000 ADSs to facilitate derivative transactions related to the notes offering [10]. - Additionally, a public offering of 5,200,000 ADSs has been announced, with underwriters granted a 30-day option for additional purchases [11].